Altogether, these data point to the upregulation of LAT1 as a salvage pathway that should be targeted instead of the well known ASCT2 transporter, to complement the effects of glucose metabolism inhibitors in cancer treatment. This evidence concerns the gene SLC7A5 and cancer.